• 2025
  • 2024
  • 2023
  • 2022
  • 2021

R&D Pipeline

R&D Pipeline (In-House)

As of February 2025

Generic name
/ Development code
Expected indications Category Development stage Development classification

Linzagolix
/ KLH-2109

Uterine fibroids GnRH receptor antagonist NDA preparation Kissei
Endometriosis Phase III preparation Kissei
CG0070 Non-muscle-invasive bladder cancer Oncolytic Viral Therapy Phase III In-licensed /
CG Oncology (U.S.)
Rovatirelin
/ KPS-0373
Spinocerebellar degeneration TRH receptor antagonist Phase III preparation In-licensed /
Shionogi (Japan)
KDT-3594 Parkinson's disease Dopamine receptor agonist Phase II Kissei




R&D Pipeline (Out-Licensing)

As of February 2025

Generic name Expected indications Category Countries & Regions Development company Development stage
Linzagolix Uterine fibroids GnRH receptor antagonist Australia Theramex (U.K.) NDA
Taiwan Synmosa Biopharma (Taiwan) NDA
Endometriosis EU Theramex (U.K.) Approved
Fostamatinib Chronic idiopathic thrombocytopenic purpura Tyrosine kinase inhibitor Korea JW Pharmaceutical (Korea) Approved
Silodosin Dysuria associated with benign prostatic hyperplasia Alpha 1A adrenergic receptor antagonist Vietnam, etc. Eisai (Japan) NDA